Zap away heartburn? new device aims to tame GERD without drugs
NCT ID NCT06613438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a device called eGERD that sends mild electrical pulses to the belly to reduce acid reflux and symptoms like heartburn. 84 adults with GERD will use either the real device or a sham version at home for several weeks. Researchers will measure acid levels in the throat and track symptom changes to see if the device is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- eGERD device (non-invasive electrical stimulation device)
- What this could lead to
- If it works, this could offer a drug-free, at-home option to ease heartburn and regurgitation for people with GERD.
- What could go wrong
- This is an early-stage trial with only 84 people, and the sham comparison means the real effect may be small. The device may not work for everyone or could cause skin irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 84 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, aged 22 - 75 2. Has been typically suffering from at least three heartburn and/or regurgitation episodes per week during the past three months. 3. Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD. 4. Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application. 5. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study. Exclusion Criteria: 1. Previously undergoing gastric or esophageal surgery 2. Active peptic ulcer disease or symptomatic helicobacter 3. Esophageal or gastric varices or esophageal peptic stricture 4. Severe dysphagia 5. History of suspected or confirmed esophageal or gastric cancer 6. History of any other malignancy in the last 2 years 7. Pregnant women or women intending to become pregnant during the trial period 8. Uncontrolled diabetes mellitus, defined as HbA1c \> 7.5% 9. Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker / defibrillator 10. Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others) 11. Known allergy to the device's adhesives/patches 12. Severe pulmonary diseases 13. History of significant multisystem diseases (e.g. kidney failure, liver failure) 14. Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years 15. History of Barrett's esophagus 16. Para-esophageal hiatal hernia 17. Known history of sliding hiatal hernia ≥4 cm in the last 3 years 18. Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years 19. Obesity, defined as BMI\>32 20. History of gastroparesis 21. History of fibromyalgia, epilepsy, endometriosis 22. Umbilical hernia \>3cm 23. Past usage experience with the study device 24. Those currently enrolled in any other interventional clinical study 25. Inability to sign the informed consent 26. Inability to understand and fill the reports and questionnaires included in the study 27. Inability to follow the study requisites 28. Other medical conditions/medications that would interfere with subject safety or data collection in the opinion of the PI
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERD (gastroesophageal reflux disease) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University
NOT_YET_RECRUITINGChicago, Illinois, 60611-2927, United States
-
Gastroenterology department, Emek medical center (EMC)
RECRUITINGAfula, Israel
-
Gastroenterology department, Rabin medical center (RMC)
RECRUITINGPetah Tikva, Israel
-
Gastroenterology department, Rambam Health Care Campus
RECRUITINGHaifa, Israel
-
Gastroenterology department, Tel Aviv Sourasky Medical Center (Ichilov)
RECRUITINGTel Aviv, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a week of acid drugs double as a GERD test?
- Smart bottle cap could reveal hidden missed doses in GERD patients
- Could a simple liquid barrier help nighttime heartburn sufferers sleep better?
- New GERD drug tegoprazan tested in large real-world study
- Can a diet and lifestyle program replace acid reflux pills after achalasia surgery?
- Fat cells injected into esophagus could tame reflux without surgery